Introduction
Pediatric acute lymphoblastic leukemia (ALL) that is caused by the Bcr/Abl oncoprotein has a poor prognosis. This type of leukemia, as well as adult chronic myelogenous leukemia (CML) and 20-30% of adult ALL are initiated by the aberrant fusion of two genes, BCR and ABL, normally located on two different chromosomes. 1, 2 Bcr/Abl has a deregulated tyrosine kinase activity, and currently the specific inhibitor Imatinib is being utilized as an effective treatment for CML. Ph-positive ALL however does not respond as well as CML to the same treatment with Imatinib, and therefore alternative or combinatorial treatment with other agents, such as farnesyltransferase inhibitors (FTIs) are under investigation. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] FTIs are a novel class of anticancer agents that target the enzyme farnesyltransferase, which is responsible for the posttranslational modification of a relatively large number of proteins by the addition of a farnesyl moiety. 13, 14 Many tumors exposed to cancer-suppressive drugs adapt to treatment by developing mechanisms of resistance, either by the de novo acquisition of genetic or epigenetic modifications, or by selection and outgrowth of a preexisting cell that is able to survive and thrive in the drug-modified microenvironment. Because drug resistance is such a common occurrence in cancer therapy, we have initiated experiments to examine the possible mechanisms by which ALL cells that express the P190 form of Bcr/Abl could become FTI-resistant.
In human patients, the leukemic cells experience the effects of drug treatment while they are present in and interact with a specific microenvironment, such as the bone marrow. Bone marrow stroma may in fact provide protection against the effects of drug therapy. [15] [16] [17] Therefore, we modeled drug therapy by growing lymphoblastic leukemia cells from a mouse model for Bcr/Abl-positive ALL 18, 19 on stromal feeder layers and exposing one set of cells to slowly escalating amounts of the FTI SCH66336, while leaving the second culture treated only with vehicle dimethyl sulfoxide (DMSO). 20 We used resistance to 16 mM FTI as a clinically relevant endpoint, as Lonafarnib/ SCH66336 is being tested in clinical trials at doses ranging from 200-400 mg/day and Awada et al. 21 reported that a 15-day regimen of 300 mg Lonafarnib in humans generates peak plasma concentrations of 2250 ng/ml, corresponding to 3.5 mM drug.
In the current study, we report that these resistant cells express N-cadherin, a cell-cell adhesion molecule associated with survival and proliferation of hematopoietic stem cells in the bone marrow. Moreover, we show that N-cadherin expression contributes to increased resistance of Bcr/Abl lymphoblasts to FTI treatment.
Materials and methods

Lymphoblastic leukemia cell lines
B-1, B-1R and B-1S cells have been described previously. 20 B-2 cells were grown in culture from the lymphoma of a 6-monthold female P190 BCR/ABL transgenic mouse. Cells were routinely grown on mitotically inactivated mouse embryonic fibroblasts (MEFs) as described. 8, 20, 22 To generate B-1 and B-2 cells able to grow in increased concentrations of SCH66336, cells were exposed to slowly (every 1-2 weeks) increasing concentrations of the drug. Media in the wells was refreshed every other day, when the cells were also treated with fresh SCH66336 or DMSO. Cell viability was assessed on aliquots from individual wells using the Trypan blue dye exclusion method.
Adhesion assays
For assays to measure adhesion to MEFs, 2 Â 10 6 (for the 30 min time point) or 1 Â 10 6 (for the 24 h time point) B-1R or B-1S cells were seeded in six-well plates containing a stromal layer. Adhesion was evaluated by counting suspended and attached cells. For N-cadherin-blocking experiments, 2 Â 10 6 B-1R and B-1S cells were incubated with mAb GC-4 (40 mg/ml, Sigma; Saint Louis, Missouri, MO, USA) or control immunoglobulin (IgG) at 371C for 30 min, washed with phosphate-buffered saline (PBS), and resuspended in PBS containing 1% bovine serum albumin and allowed to adhere to MEFs for 30 min. After removal of nonadherent cells, the number of adherent cells in triplicate wells was counted. Bright field images of the cells in PBS were taken using a Hamamatsu (Bridgewater, NJ, USA) ORCA-ER digital CCD camera and Compix (Cranberry Township, PA, USA) SimplePCI acquisition software. Images were captured with a Leica Microsystems (Wetzlar, Germany) MZ FL III motorized fluorescence stereomicroscope with a 1 Â PlanApo lens and Â 10 zoom. Images were processed using Photoshop (Adobe Systems).
Western blot and immunofluorescence
Anti-N-cadherin antibodies used for Western blotting were from Zymed Laboratories Inc. (San Francisco, CA, USA). For immunofluorescence assays, we used anti-N-cadherin GC-4 antibodies (Sigma) on paraformaldehyde-fixed lymphoma cells seeded on 0.01% poly-L-lysine-coated chamber slides. Cells were permeabilized with 0.2% Triton X-100 for 10 min. Cells were examined by Leica DM RXA/RF-8 upright fluorescence microscopy with an Optovar 1.25 Â and Â 40 objective lens. Images of the cells were taken using a SKY SD-300/VDS-1300 digital CCD camera and EasyFish software (Applied Spectral Imaging Inc., Carlsbad, CA, USA). Images were processed using Photoshop (Adobe Systems, San Jose, CA, USA).
FACS analysis
Double flow cytometry was performed using a FACScan (Beckton Dickinson, Franklin Lakes, NJ, USA) and Sca-1, surface IgM, CD24, CD43, Mac-1, Gr-1, B220/CD45R, Thy-1.2. antibodies (BD-PharminGen, Franklin Lakes, NJ, USA). For FACS analysis of anti-N-cadherin, 1 Â 10 6 cells were fixed in 4% paraformaldehyde in PBS for 10 min, washed with PBS once, incubated with 2 mg anti-N-cadherin antibody GC-4 in 100 ml PBS/3% fetal bovine serum for 30 min, washed with PBS twice, then incubated with the second antibody FITC-goat anti-mouse IgG for 30 min.
Lentiviral transduction
Human N-cadherin cDNA (NM_001792, Origene, Rockville, MD, USA) was cloned into the bicistronic vector pCCL-PGK-EGFP (CHLA Vector Core, Los Angeles, CA, USA). The lentiviral vector containing N-cadherin or the empty vector expressing only EGFP were cotransfected with packaging plasmid PAX2 and envelope plasmid pMD2G (obtained from Didier Trono, University of Geneva, Switzerland) into 293FT cells (Invitrogen, Carlsbad, CA, USA), and viral supernatants were harvested and concentrated after 72 h. The original B-1 lymphoma cells were transduced with concentrated lentiviral supernatants and cultured for a few days. The EGFP-positive cells were collected by flow sorting.
Statistical analysis
Significance testing was done using Student's t-test, where a Po0.05 was considered statistically significant.
Results
Stromal cells provide protection to lymphoblasts in surviving FTI drug treatment
To investigate the effect of stroma on lymphoblastic leukemia cells during FTI treatment, we followed a line of BCR/ABL lymphoblasts, B-2, upon treatment with 0.25 mM SCH66336 for an extended period of time. As shown in Figure 1a , drug treatment caused a large decrease in the number of viable cells during the first few days of treatment, regardless of the absence or presence of stromal support. However, B-2 cells lacking stromal support were essentially eradicated after 4 days of drug treatment. In contrast, those provided with stromal support resumed proliferation, and after 10 days of culture, the cells were able to grow in the presence of 0.25 mM SCH66336 (Figure 1a) .
B-1 lymphoblastic leukemia cells were independently derived from a different BCR/ABL P190 transgenic mouse. B-1R lymphoblastic leukemia cells were derived from these by progressive exposure to increasing FTI concentrations and are resistant to 16 mM FTI, whereas B-1S cells are drug-sensitive but were grown in culture for the same period of time as the B-1R cells. 20 We also treated the B-1R cells with a doubled dose, of 32 mM FTI, for 48 h. The increased drug concentration did affect the B-1R cells, but nonetheless, the stromal layer still provided a survival benefit to the lymphoblastic leukemia cells (Figure 1b) .
Interaction of FTI-resistant lymphoblastic leukemia cells with stroma
We next compared the phenotype of B-1R and B-1S cells. B-1R cells proliferated more slowly than the B-1S cells, both on stroma and in the absence of it. The stroma did provide a growth benefit, as the numbers of cells recovered after 72 h of growth was about 1.7-fold higher for the B-1S cells and twofold higher for the B-1R cells grown on MEFs, than comparable cells not grown on MEFs (Supplementary Figure 1a) . Cell cycle analysis confirmed that the B-1R cells had a lower percentage of cells in G2/M (Supplementary Information Figure 1c) . We considered the possibility that this reduced overall proliferation rate of the B-1R cells was a result of acute exposure to SCH66336. However, when the cells were cultured without SCH66336 for 1.5 months, the difference in growth rate between B-1R and B-1S remained (Supplementary Figure 1b) , indicating that this is an intrinsic property of the B-1R cells.
In passaging the B-1R cells, we also remarked that these cells were more difficult to detach from the feeder layer than the B-1S cells. We therefore first investigated whether this was caused by increased integrin-mediated adhesion to fibronectin. However, the B-1R cells had a similar degree of adhesion to fibronectin as the B-1S cells (Supplementary Figure 1d) .
When we compared the adhesion of the B-1R and the B-1S cells to the stromal cell layer, we found that within 24 h, an increased number of B-1R cells adhered to and underneath the fibroblasts compared to the B-1S cells ( Figure 1c , left panel). In addition, motility of B-1R cells toward the chemokine SDF-1a in Transwell assays was higher than that of the B-1S cells ( Figure 1c , right panel). These results showed that the B-1R cells differ from the B-1S cells in decreased proliferation and a more avid association with the fibroblast layer.
We then evaluated the contribution of the fibroblast-leukemia cell-cell contact to surviving drug treatment. We compared the viability and absolute cell numbers of B-2 cells treated with 0.25 mM SCH66336 in direct contact with the MEFs to identically treated cultures in which the two populations were physically separated by a membrane. As shown in Figure 1d , direct physical contact provided an extra survival benefit to the cells.
Expression of N-cadherin in Bcr/Abl lymphoblastic leukemia cells
To compare the B-1R and B-1S cells for differences in gene expression, RNA was isolated from both populations after the B-1R cells had reached the ability to proliferate in 16 mM SCH66336. Microarray analysis showed the altered expression of many genes (results not shown). Among genes of which the expression was modulated more than tenfold, (Supplementary Information, Supplementary Table 1), we focused on N-cadherin, with a 13-fold increased expression in the B-1R cells, because it is a protein that mediates cell-cell adhesion.
Western blot analysis using pan-cadherin (not shown) and N-cadherin antibodies showed that the total B-1S population as well as the total original B-1 cell population expressed very low to undetectable amounts of N-cadherin ( Figure 2a To examine if the increased expression of N-cadherin was found on only a subpopulation of B-1R cells, or that all the cells expressed it, we performed N-cadherin immunostaining. This analysis (Figure 2b) showed that all the B-1R cells expressed N-cadherin, whereas it was not detectable in the B-1S cells using this method. Therefore, we conclude the process of coculturing Bcr/Abl-positive lymphoblasts with MEFs, on its own, does not induce N-cadherin expression.
To examine if the increased expression of N-cadherin was explained by amplification of the endogenous murine gene, we karyotyped the B-1 and B-1R cells. This showed that the original B-1 cells contained a trisomy 13 as sole abnormality, whereas the B-1R cells had additional gains of whole chromosomes including chromosome 18, which contains N-cadherin (Supplementary Information, Figure 3a and b) . Southern blotting using an N-cadherin probe was consistent with the presence of one extra copy of the N-cadherin gene in B-1R (Supplementary Figure 3) . The 13-fold increased N-cadherin mRNA levels can therefore not be completely explained by increased dosage (one extra copy) of the N-cadherin gene in the B-1R cells.
N-cadherin on the B-1R cells facilitates their adhesion to and/or migration underneath the stromal cells Does the N-cadherin expression on B-1R cells functionally contribute to the increased adhesion of these cells to the MEFs? To test this, we used function-blocking antibodies against N-cadherin to assess the effect of the expression of this adhesion protein on the B-1R cells. We first tested the effect of these antibodies on the formation of cell-cell aggregates between the lymphoblastic leukemia cells, but results did not support the possibility that the N-cadherin expressed on the B-1R cells was utilized for this (not shown). We then examined the effect of N-cadherin expression on adhesion to MEFs. In a short-term adhesion assay, within a 30 min period after plating, 14.6% of input B-1S cells were protected from being removed from the MEF layer, whereas 32.7% of B-1R cells were firmly attached (Figure 2c ). When the B-1R cells were preincubated with N-cadherin function-blocking antibodies and then tested for their ability to adhere to the MEFs, their adhesion to the MEFs was significantly reduced; whereas B-1R cells pretreated with control IgG (Figure 2d 
Emergence of N-cadherin-expressing lymphoblastic leukemia cell populations
We considered the possibility that the emergence of N-cadherin-expressing cells was an event that had uniquely occurred in the B-1R population during the development of drug resistance. To investigate this, we repeated the gradual exposure of the original drug-sensitive B-1 cells to SCH66336, and also exposed the second lymphoblastic leukemia line that was derived from a different BCR/ABL P190 transgenic mouse, B-2, to increasing concentrations of SCH66336. FACS was performed during this process at 0.25 mM for B-2 and at a higher concentration of 1 mM for B-1. As shown in Figure 3a Table 1 ). Also, the B-1R cells expressed 3-6-fold decreased levels of Ly64, TDT, BLNK and IL-7R (not shown). This suggested that the B-1R cells were, overall, less differentiated. Therefore, we performed immunophenotyping of the original B-1, B-1S, B-1R and B-2 cells as well as B-1 and B-2 cells during emergence of resistance to increased FTI concentrations. Although small differences were seen in the percentage of the brighter staining B220 þ populations, the largest differences were noted in the CD24 (heat stable antigen) marker. We found that the original population of B-1 cells, which had never been treated with FTI and had been frozen relatively soon after isolation of the cells from the mouse, was mostly CD24, CD43 double positive (91% of the total), with about 7% of the cells CD43 þ , CD24À (Figure 4a, left panel) .
The B-1S cells, which had been cultured for a similar period of time as the B-1R cells, became uniformly CD43, CD24 positive ( Figure 4a, middle panel) . However, all B-1R cells were CD43 þ , CD24À (Figure 4a , right panel).
Progressive de novo treatment of the original B-1 cells with FTI resulted in a shift toward increasing loss of CD24 (Figure 4b , upper panels), and this was also seen, to a lesser extent, in the independently derived B-2 cells when they had become resistant to 10 mM FTI (Figure 4b, lower panels) . When original B-1 cells which had not been exposed to FTI were sorted into a CD24 þ and a CD24À population, the CD24À population gave rise to a percentage of CD24 þ cells (not shown), consistent with the fact that CD43 þ , CD24 þ cells are more mature than CD43 þ , CD24À cells. 23, 24 Western blot analysis of the sorted CD24À and CD24 þ fractions showed that the CD24À fraction expressed more N-cadherin (Figure 4c ). When the CD24À and CD24 þ cells were treated with 1 mM SCH66336, the CD24À cells had higher viability after 48 h of treatment (Figure 4d ). Based on these data, we conclude that the original B-1 cell population contained a small subset of more primitive cells that express N-cadherin, and are also more resistant to FTI treatment.
Forced N-cadherin expression confers increased FTI resistance to B-1 lymphoblastic leukemia cells
Next, we sought to address the question if N-cadherin expression promotes increased resistance to SCH66336. Although treatment of B-1R with N-cadherin function-blocking antibodies followed by FTI treatment could potentially have provided insight into this issue, this was technically not feasible with the antibodies used. Therefore, we alternatively sought to overexpress N-cadherin in nonexpressing Bcr/Abl-positive lymphoblasts. As the transfection efficiency of such cells is prohibitively low, we generated a lentiviral construct encoding N-cadherin and introduced N-cadherin and control EGFP into the B-1 lymphoblasts using lentiviral transduction. As shown in Figure 5a , this procedure resulted in the generation of B-1 cells that clearly expressed N-cadherin. We then treated both cell populations with 0.25 mM FTI for 48 h, both in the absence or presence of MEFs. Interestingly, when the cells were not grown in the presence of fibroblasts, N-cadherin had no impact on cell survival, and only about 20% of the cells were viable after 48 h.
In comparison with cells transduced with control EGFP lentivirus, the N-cadherin-expressing cells showed increased survival on fibroblast feeder layers when they were treated with FTI for 2 days (Figure 5b ). These results establish that N-cadherin expression is one factor that contributes to the ability of the lymphoblastic leukemia cells to survive treatment with the FTI SCH66336 in the presence of stromal support.
Discussion
In the current study, we treated lymphoblastic leukemia cell populations derived from Bcr/Abl transgenic mice with an FTI in the presence of stroma. Although it was not difficult to eradicate the bulk of the cells with concentrations as low as 0.25 mM SCH66336, a small population of cells remained viable and subsequently grew out. These cells could be rare individual subclones with preexisting mutations that are selected because those confer survival benefit. It is also possible that the original input population consisted of a mixture of more and less differentiated cells and that drug treatment selectively destroyed the more differentiated cells, but left the more primitive cells alive. There is increasing evidence that this is what happens in human CML patients who are treated with Imatinib. 25 Imatinib treatment of CML patient cells resulted in the enrichment of an Imatinib-resistant primitive population, and nonproliferating CML progenitors were found to be particularly resistant to induction of apoptosis. 26, 27 Although our own results do not provide any evidence to support or refute the first possibility, our data do suggest that the second mechanism may provide an explanation for some of our observations.
According to the Hardy classification 23,24 the B220 þ , CD43 þ pre-B population can be further subdivided into a CD24À pre-proB and a CD24 þ proB population. Immunophenotyping showed the original B-1 cells were mostly CD24 þ , CD43 þ , but also that 7% of cells were CD24À, CD43 þ . However, after culture for 3 months, the B-1S cells were all CD24 þ , CD43 þ . This suggests that either the CD24À cells differentiated into CD24 þ cells, and/or that the CD24À had a selective disadvantage in comparison with the CD24 þ cells (i.e., if they proliferated more slowly) under these culture conditions and, over time, were lost. In contrast, when exposed to escalating concentrations of FTI, after 3 months all of the B-1R cells were CD24À, CD43 þ . As CD24À, CD43 þ cells are more primitive than CD24 þ , CD43 þ cells, we conclude that the treatment with the FTI in the presence of stroma caused the preferred selection of a more slowly proliferating, primitive population of pre-proB precursor cells.
N-cadherin mediates homotypic cell-cell interactions and was initially thought to be expressed only on neuronal, endothelial, fibroblast and muscle cells. However, Puch et al. 28 reported N-cadherin expression on a CD34 þ , CD19 þ subpopulation of early hematopoietic progenitor cells. These cells are thought to be early B-lymphoid progenitors that can still develop into the myeloid lineage.
28 N-cadherin also mediates adhesion between hematopoietic stem cells and the osteoblasts that form the HSC niche. 29 The data indicate that Ncadherin can be considered a marker for more primitive hematopoietic cells and our finding that it is expressed on the CD24À B-1R cells is consistent with their less differentiated state.
Very little is known about the function of N-cadherin in hematopoietic stem cells (see review Wilson and Trumpp 30 ). In other cell types it has been more extensively investigated, and it was shown to play an important role in maintaining the balance in the pool of b-catenin that is available for transcriptional activation: elevated N-cadherin levels can result in increased sequestration of b-catenin at the cell periphery, leading to a decreased pool of b-catenin available for activation of target genes (see review Nelson and Nusse 31 ). However, our microarray analysis on the N-cadherin-overexpressing B-1R cells showed increased expression of some typical b-catenin/lymphoid enhancer factor (LEF)/T-cell factor (TCF) target genes, such as cyclin D1 and a downregulation of RAMP3 32 (Supplementary Information, Supplementary Table 1) , which would be more consistent with increased b-catenin activation. Finally, the N-cadherin-b-catenin interaction can also be regulated by tyrosine phosphorylation in other cell types, 33 and therefore the significance of our observed tyrosine phosphorylation of N-cadherin by Bcr/Abl warrants further investigation. Additionally, we did not measure significantly different levels of activated Akt in B-1R and B-1S cells ( Supplementary  Information, Figure 2b ), a finding that was reported in a study, in which a colorectal carcinoma cell line was intentionally made SCH66336-resistant. 34 Therefore, the molecular mechanisms by which N-cadherin expression mediates protection against FTI is currently unclear and will require further investigation.
We showed, that B-1 CD24À cells have an inherent increased ability to resist treatment with 0.25 mM FTI as compared to the B-1 CD24 þ cells, and that they have low but detectable N-cadherin expression. Furthermore, the elevated level of N-cadherin in the B-1R lymphoma cells facilitates their adhesion to and migration underneath the stroma cells. This suggests that the reason the more primitive B-1R cells were selected from the bulk of the B-1 cells is that their N-cadherin expression provided a selective advantage over the other cells during drug treatment by allowing a homotypic interaction with the N-cadherin-expressing fibroblasts. This selection only occurred when the cells were placed under circumstances of drug exposure and was not merely the result of coculture of Bcr/ Abl-positive lymphoblasts with MEFs, because there was little N-cadherin expression in the bulk of the original leukemia cells.
The difference in viability between B-1 cells expressing lentiviral-transduced EGFP or N-cadherin after 48 h of drug treatment was significant but not remarkably large. Clearly, besides the contribution of N-cadherin, the stromal cells provide additional survival benefits to the malignant lymphoblasts. Our experiments, in which B-1 leukemic cells were separated from the fibroblasts by a membrane clearly supports this concept: the MEFs secrete soluble factors that aid the cells in surviving FTI treatment, but optimal survival is obtained when cell-cell contact takes place. Indeed, on long-term drug treatment in the presence of stroma, N-cadherin-expressing cells were reproducibly obtained, indicating that N-cadherin must be of significance to the long-term survival of the cells. This finding suggests, that if it were possible to dislodge these more primitive N-cadherin-expressing cells from the stromal layer, they would be more vulnerable to FTI treatment. To translate this finding into a clinically useful treatment will be a challenge because normal hematopoietic stem cells also utilize N-cadherin for contact with the stem cell niche. Nonetheless, if human preproB ALL cells or the potential leukemia stem cell that gives rise to them similarly utilize N-cadherin-mediated adhesion for survival and proliferation when exposed to other types of drugs, including those used for chemotherapy, this could potentially be used to design supportive therapy to make chemotherapy more effective.
